Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIFETRAIN: Personalised Pharmaco-Lifestyle Interventions for Severe Mental Illnesses
NCT07586150Not yet recruiting
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Oct 2028
- Primary completion
- Jul 2030
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Randomised, single-blind trial of semaglutide in severe mental illness (SMI), schizophrenia, bipolar disorder (BD) and 3 more (2 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Short Form 36 Health Survey Mental Component Summary at Month 3. Planned start Oct 2028; status: not yet recruiting.
02
Drugs
03
Conditions
severe mental illness (SMI)schizophreniabipolar disorder (BD)major depressive disorder (MDD)Overweight
Beyond the preview
Go deeper on NCT07586150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586150.